← Back

Jiangsu Yahong Meditech Co. Ltd.

Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic drug-device combination product for the treatment of high-grade squamous intraepithelial lesions of the cervix and for HPV viral clearance; APL-2302, an oral small-molecule inhibitor of the deubiquitinating enzyme ubiquitin-specific protease 1 (USP1) for the treatment of ovarian and breast cancer; APL-2501 for the treatment of ovarian cancer; AT-018 for the treatment of breast cancer; and AT-021 for the treatment of breast cancer and other solid tumors. The company also develops APL-1706 and APLD-2304 for non-muscle-invasive bladder cancer (NMIBC) diagnosis and surgery; APL-1202 for Untreated intermediate-risk NMIBC and neoadjuvant therapy before MIBC; and APL-2401 for urinary tumors. In addition, it develops APL-1202 for the treatment of free-living amoeba infection; APL-1401 for moderate to severe active ulcerative colitis; and APL-2301, an antibiotic for Acinetobacter baumannii infection. The company was incorporated in 2010 and is based in Shanghai, China.

Price · split & dividend adjusted
News & notes moving 688176.CG
Biotech & Genomic Medicine▲

FDA Approves Clinical Trial for APL-2501 by Yahong Medtech Subsidiary

Baylink Biosciences Inc, a controlled subsidiary of Yahong Medtech, has received approval from the U.S. Food and Drug Administration for an investigational new drug application for APL-2501 for the treatment of advanced solid tumors. APL-2501 is an antibody-drug conjugate based on a topoisomerase inhibitor, expected to be useful in treating multiple advanced solid tumors such as ovarian cancer and non-small cell lung cancer. In the first quarter of 2026, Yahong Medtech recorded revenue of 71.09 million yuan and a net loss attributable to the parent company of 112 million yuan.
688176.CG ▲
Biotech & Genomic Medicine
财中社·13dRead more ▾
688176.CG▼

Asieris Pharmaceuticals Faces Arbitration as Photocure Seeks 4.4 Million Dollars in Milestone Payments

Asieris Pharmaceuticals and its wholly-owned subsidiary Asieris Meditech Hong Kong Co., Ltd. have been taken to arbitration by Photocure before the American Arbitration Association over a dispute concerning milestone payments under the APL-1702 license agreement, with Photocure seeking 4.4 million dollars plus interest. Photocure granted Asieris an exclusive worldwide license for APL-1702, and the company had previously paid all triggered milestone amounts. Following the approval and launch of APL-1702, marketed as CEVIRA, in China in March 2026, Asieris paid 6.6 million dollars in April 2026, but contends that this approval did not trigger the full 11 million dollar payment obligation for that milestone, whereas Photocure asserts that the payment conditions have been met. In the first quarter of 2026, Asieris reported revenue of 71.09 million yuan and a net loss attributable to the parent company of 112 million yuan.
0IMT.LSE ▲688176.CG ▼
财中社·35dRead more ▾
© 2026 MarketDXAsset